Loading clinical trials...
Loading clinical trials...
Tuberculosis is one of the major health problems in developing countries. Isoniazid, rifampin and pyrazinamide, the first line drugs used for tuberculosis chemotherapy, are associated with hepatotoxic...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
National Research Institute of Tuberculosis and Lung Disease, Iran
NCT03587831 · NASH - Nonalcoholic Steatohepatitis
NCT04923958 · Tuberculosis
NCT06590428 · Rifampin-resistant Tuberculosis, Drug-resistant Tuberculosis
NCT07417553 · Chronic Hepatitis B-related Liver Fibrosis
NCT05623150 · Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, and more
National Research Institute of Tuberculosis and Lung Disease (NRITLD)
Tehran
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions